Novation Companies

Novation Pharmaceuticals is a biopharmaceutical company specializing in the discovery of small molecule drugs that modulate the stability of messenger RNA (mRNA). The company's proprietary Quest platform enables the identification of compounds that can selectively increase or decrease the half-life of specific mRNAs, thereby regulating the production of disease-causing proteins. Novation's research focus includes high-value targets in oncology, such as c-myc, and neurodegenerative disorders, specifically Amyotrophic Lateral Sclerosis (ALS). The company collaborates with academic and industry partners, including the University of Montreal and Cancer Therapeutics CRC, to advance its pipeline of RNA-targeted therapies.